Educational Case: Membranous Nephropathy.

http://journals.sagepub.com/doi/10.

Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.

Aim: To investigate the relationship between effective fentanyl sublingual spray (FSS) doses for breakthrough cancer pain (BTCP) and around-the-clock (ATC) transdermal fentanyl patch (TFP).

Methods: Adults tolerating ATC opioids received open-label FSS for 26 days, followed by a 26-day double-blind phase for patients achieving an effective dose (100-1600 µg).

Results: Out of 50 patients on ATC TFP at baseline, 32 (64%) achieved an effective dose.

Nutrition Information In Community Newspapers: Goal Framing, Story Origins, and Topics.

Obesity rates are high in the rural United States. Because small communities often have few health care practitioners, nutrition news in community newspapers may be a useful source of information. This content analysis of a random sample of 164 nutrition stories from 10 community newspapers in the rural West North Central Midwest was guided by concepts from goal-framing theory.

SPECT-negative SIRPIDs: less aggressive neurointensive care?

Introduction: The management of EEG patterns in comatose intensive care unit patients remains poorly studied regarding whether aggressive management improves outcomes. We hypothesized that stimulus-induced rhythmic, periodic, or ictal discharges (SIRPIDs) could be classified as ictal and interictal using single-photon emission computerized tomographic (SPECT) imaging to help guide aggressive or deescalate anticonvulsant management.

Methods: We performed a retrospective review of all cases of ICU patients at a single center, tertiary care academic center for evidence of SIRPIDs with concomitant SPECT imaging over a one year period.

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.

Background: Imiquimod 3.75% and 2.5% creams were studied for the treatment of actinic keratosis (AK) of the full face or balding scalp, to determine comparable efficacy and tolerability to imiquimod 5% cream.

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.

Background: Imiquimod 3.75% and 2.5% creams were studied for the treatment of actinic keratosis (AK) of the full face or balding scalp, to determine comparable efficacy and tolerability to imiquimod 5% cream.

True- true- unrelated? A delayed onset, complete third-nerve palsy after traumatic subarachnoid hemorrhage.

Unlabelled: A 61-year-old male presented to the emergency department (ED) with painless diplopia, left-ptosis, and left downward gaze, 3 days after sustaining a fall from standing height with subsequent lumbar and head trauma. Prior to the ED consult, his only symptom was persistent generalized high intensity headache. On physical examination, no other neurological deficit was found.